Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up | Rheumatoid Arthritis | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.226.234.102. Please contact the publisher to request reinstatement.
1.
Baert F, Noman M, Vermeire S,  et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.  N Engl J Med. 2003;348(7):601-60812584368PubMedGoogle ScholarCrossref
2.
Wolbink GJ, Vis M, Lems W,  et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.  Arthritis Rheum. 2006;54(3):711-71516508927PubMedGoogle ScholarCrossref
3.
Bartelds GM, Wijbrandts CA, Nurmohamed MT,  et al.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.  Ann Rheum Dis. 2007;66(7):921-92617301106PubMedGoogle ScholarCrossref
4.
van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis.  Ann Rheum Dis. 2010;69(3):624-62520223840PubMedGoogle ScholarCrossref
5.
Lecluse LL, Driessen RJ, Spuls PI,  et al.  Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.  Arch Dermatol. 2010;146(2):127-13220157022PubMedGoogle ScholarCrossref
6.
Calabresi PA, Giovannoni G, Confavreux C,  et al; AFFIRM and SENTINEL Investigators.  The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.  Neurology. 2007;69(14):1391-140317761550PubMedGoogle ScholarCrossref
7.
West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.  Aliment Pharmacol Ther. 2008;28(9):1122-112618691349PubMedGoogle ScholarCrossref
8.
Allez M, Karmiris K, Louis E,  et al.  Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.  J Crohns Colitis. 2010;4(4):355-36621122530PubMedGoogle ScholarCrossref
9.
Karmiris K, Paintaud G, Noman M,  et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.  Gastroenterology. 2009;137(5):1628-164019664627PubMedGoogle ScholarCrossref
10.
Bartelds GM, Wijbrandts CA, Nurmohamed MT,  et al.  Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.  Ann Rheum Dis. 2010;69(5):817-82119581278PubMedGoogle ScholarCrossref
11.
Bartelds GM, de Groot E, Nurmohamed MT,  et al.  Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study.  Arthritis Res Ther. 2010;12(6):R22121187010PubMedGoogle ScholarCrossref
12.
Furst DE, Breedveld FC, Kalden JR,  et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.  Ann Rheum Dis. 2007;66:(suppl 3)  iii2-iii2217934088PubMedGoogle ScholarCrossref
13.
Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.  Arthritis Rheum. 1995;38(1):44-487818570PubMedGoogle ScholarCrossref
14.
Wolbink GJ, Voskuyl AE, Lems WF,  et al.  Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.  Ann Rheum Dis. 2005;64(5):704-70715485995PubMedGoogle ScholarCrossref
15.
van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients.  J Immunol Methods. 2010;362(1-2):82-8820833178PubMedGoogle ScholarCrossref
16.
Blom M, Kievit W, Kuper HH,  et al.  Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.  Arthritis Care Res (Hoboken). 2010;62(9):1335-134120506128PubMedGoogle ScholarCrossref
17.
Jamnitski A, Bartelds GM, Nurmohamed MT,  et al.  The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.  Ann Rheum Dis. 2011;70(2):284-28821068090PubMedGoogle ScholarCrossref
18.
Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.  Gut. 2007;56(9):1226-123117229796PubMedGoogle ScholarCrossref
19.
Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review.  Arthritis Res Ther. 2010;12(5):21721029481PubMedGoogle ScholarCrossref
20.
Bartelds GM, Wijbrandts CA, Nurmohamed MT,  et al.  Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.  Arthritis Rheum. 2009;60(8):2541-254219644871PubMedGoogle ScholarCrossref
21.
Miyasaka N.CHANGE Study Investigators.  Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study.  Mod Rheumatol. 2008;18(3):252-26218330677PubMedGoogle ScholarCrossref
22.
Radstake TR, Svenson M, Eijsbouts AM,  et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.  Ann Rheum Dis. 2009;68(11):1739-174519019895PubMedGoogle ScholarCrossref
23.
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.  Arthritis Rheum. 2006;54(12):3782-378917133559PubMedGoogle ScholarCrossref
Original Contribution
April 13, 2011

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

Author Affiliations

Author Affiliations: Jan van Breemen Research Institute (Drs Bartelds, Krieckaert, Nurmohamed, and Wolbink); VU Medical Center (Drs Nurmohamed, Lems, Twisk, and Dijkmans); and Sanquin Research and Landsteiner Laboratory Academic Medical Centre (Ms van Schouwenburg and Drs Aarden and Wolbink), Amsterdam, the Netherlands.

JAMA. 2011;305(14):1460-1468. doi:10.1001/jama.2011.406
Abstract

Context Short-term data on the immunogenicity of monoclonal antibodies showed associations between the development of antidrug antibodies and diminished serum drug levels, and a diminished treatment response. Little is known about the clinical relevance of antidrug antibodies against these drugs during long-term follow-up.

Objective To examine the course of antidrug antibody formation against fully human monoclonal antibody adalimumab and its clinical relevance during long-term (3-year) follow-up of patients with rheumatoid arthritis (RA).

Design, Setting, and Patients Prospective cohort study February 2004-September 2008; end of follow-up was September 2010. All 272 patients were diagnosed with RA and started treatment with adalimumab in an outpatient clinic.

Main Outcome Measures Disease activity was monitored and trough serum samples were obtained at baseline and 8 time points to 156 weeks. Serum adalimumab concentrations and antiadalimumab antibody titers were determined after follow-up. Treatment discontinuation, minimal disease activity, and clinical remission were compared for patients with and without antiadalimumab antibodies.

Results After 3 years, 76 of 272 patients (28%) developed antiadalimumab antibodies—51 of these (67%) during the first 28 weeks of treatment. Patients without antiadalimumab antibodies had much higher adalimumab concentrations (median, 12 mg/L; IQR, 9-16 mg/L) compared with patients with antibody titers from 13 to 100 AU/mL (median, 5 mg/L; IQR, 3-9 mg/L; regression coefficient, −4.5; 95% CI, −6.0 to −2.9; P < .001) and also those greater than 100 AU/mL (median, 0 mg/L; IQR, 0-3 mg/L; regression coefficient, −7.1; 95% CI, −8.4 to −5.8; P < .001). Patients with antiadalimumab antibodies more often discontinued participation due to treatment failure (n = 29 [38%]; hazard ratio [HR], 3.0; 95% CI, 1.6-5.5; P < .001) compared with antiadalimumab antibody–negative ones (n = 28 [14%]). Ninety-five of 196 patients (48%) without antiadalimumab antibodies had minimal disease activity vs 10 of 76 patients (13%) with antiadalimumab antibodies; patients with antiadalimumab antibodies less often had sustained minimal disease activity score in 28 joints (DAS28) (< 3.2; HR, 3.6; 95% CI, 1.8-7.2; P < .001) compared with antiadalimumab antibody–negative ones. Three of 76 patients (4%) with antiadalimumab antibodies achieved sustained remission compared with 67 of 196 (34%) antiadalimumab antibody–negative ones; patients with antiadalimumab antibodies less often achieved remission (DAS28 < 2.6; HR, 7.1; 95% CI, 2.1-23.4; P < .001) compared with antiadalimumab antibody–negative ones.

Conclusion Among outpatients with RA in whom adalimumab was started over 3 years, the development of antidrug antibodies was associated with lower adalimumab concentration and lower likelihood of minimal disease activity or clinical remission.

×